- Yingqun Wang, MDBiomedSci, 1500 E Duarte RD, Duarte, CA 91010 USAInterests: Cancer Biology: 30 Publications, 3 Grants, Editor of Frontiers in Bioscience Special Issue: Cell cell Adhesion and Communications in Development and TumorigenesisSpecial Issues and Topics in IMR Press journals
- Haihua Feng, MDCity of Hope National Medical CenterInterests: Cancer Biology; Biochemistry; DNA Damage/Repair; DNA Replication; Radiation Therapy
Early diagnosis, personalized treatment and biomarker-directed prognosis are the key components for the management of cancer patients. It has been well documented that the earlier the diagnosis is performed, the better will be the clinical outcome of cancer patients. Moreover, a thorough and accurate cancer diagnosis is the first step in developing an individualized cancer treatment plan. There are varieties of ways for cancer screening including physical exam, imaging test, blood test and biopsy. Although screening test can find tumors at its early stage, falsely positive or falsely negative screening test results remain a challenge for the doctors. A reliable diagnosis is essential for cancer therapy. Discovery of novel tumor biomarkers is an important way in the development of cancer diagnosis. The current next generation sequencing may provide instructions for cancer patient stratification and treatment plan decision. Moreover, the development of robust tumor cell-free circulating DNA screening in distinct cancer types is a promising method for early diagnosis of cancer.
Genetic and epigenetic alterations, which contribute to cancer cell growth, metastasis and escape from immunosurveillance, vary among patients. Especially, the complexity of genetic alteration of cancer cells poses a challenge in precise treatment for decades. The conventional cancer treatments such as surgery, radiation therapy, chemotherapy, hormone therapy and targeted therapy have improved the benefit of cancer patients, but many patients become resistant to these treatments and die from relapse. It is urgent to develop novel therapy strategies to increase therapeutic windows by reducing the side effects of current available cancer treatment modules. In particular, immunotherapy and oncolytic adenovirus vector based targeted therapy have shown promise in preclinical studies.
In this special issue we will bring experts in the field to communicate their findings on the development of novel approaches to cancer diagnosis and therapy. We hope that such efforts will contribute to better management of cancer patients in the clinic.
Dr. Yingqun Wang and Dr. Haihua Feng
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.
- The “SEED” Study: The Feasibility of Selecting Patient-Specific Biologically Targeted Therapy with Sorafenib, Everolimus, Erlotinib or Dasatinib for Pediatric and Young Adult Patients with Recurrent or Refractory Brain TumorsBonnie L. Cole, Kimberly Starr, Christina M. Lockwood, Sarah E. S. LearyFront. Biosci. (Landmark Ed) 2022, 27(7), 219; https://doi.org/10.31083/j.fbl270721946Download214Views
- Deep Learning Empowers Lung Cancer Screening Based on Mobile Low-Dose Computed Tomography in Resource-Constrained SitesJun Shao, Gang Wang, Le Yi, Chengdi Wang, ... Weimin LiFront. Biosci. (Landmark Ed) 2022, 27(7), 212; https://doi.org/10.31083/j.fbl270721277Download4Citations220Views
- The state of therapy modalities in clinic for biliary tract cancerWeixun Chen, Zhengnan Hu, Jia Song, Yu Wu, ... Lei ZhangFront. Biosci. (Landmark Ed) 2022, 27(6), 185; https://doi.org/10.31083/j.fbl270618589Download243Views
- KMT2C is a Potential Biomarker of Anti-PD-1 Treatment Response in Metastatic MelanomaKuixia Xie, Yonglin Peng, Wenying Zhong, Xinhua LiuFront. Biosci. (Landmark Ed) 2022, 27(3), 103; https://doi.org/10.31083/j.fbl270310390Download2Citations262Views
- Deep learning quantification of vascular pharmacokinetic parameters in mouse brain tumor modelsChad A. Arledge, Deeksha M. Sankepalle, William N. Crowe, Yang Liu, ... Dawen ZhaoFront. Biosci. (Landmark Ed) 2022, 27(3), 99; https://doi.org/10.31083/j.fbl2703099107Download345Views
- Cytofluorimetric assay to investigate variability in blinatumomab in vitro responseStefania Braidotti, Raffaella Franca, Marilena Granzotto, Elisa Piscianz, ... Giuliana DecortiFront. Biosci. (Landmark Ed) 2022, 27(2), 39; https://doi.org/10.31083/j.fbl270203945Download246Views
- Airway local endoscopic pharmacological treatment; current applications and future conceptsPaul Zarogoulidis, Christoforos Kosmidis, Konstantinos Sapalidis, Wolfgang Hohenforst-Schmidt, ... Chrysanthi SardeliFront. Biosci. (Landmark Ed) 2022, 27(1), 36; https://doi.org/10.31083/j.fbl2701036438Download205Views
- Unfolded protein response activated by endoplasmic reticulum stress in pancreatic cancer: potential therapeutical targetDi Long, Kai Chen, Yinmo Yang, Xiaodong TianFront. Biosci. (Landmark Ed) 2021, 26(12), 1689–1696; https://doi.org/10.52586/506156Download1Citations183Views
- Tropism and transduction of oncolytic adenovirus vectors in prostate cancer therapyChuang Wu, Fu-kun Wei, Zi-yang Xu, Ru-min Wen, ... Li-jun MaoFront. Biosci. (Landmark Ed) 2021, 26(10), 866–872; https://doi.org/10.52586/499357Download177Views